first patients treated in jCyte_Thumbnail
August 20, 2025

First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa

jCyte turns up the dose, chasing broader answers for a disease with few options.  A higher dose, a broader target…

Artboard 1
June 9, 2025

ViGeneron Rebrands as VeonGen Therapeutics, Accelerates Clinical Pipeline in IRDs

VeonGen Therapeutics debuts with FDA recognition and bold plans for inherited eye diseases.  ViGeneron (Munich, Germany) announced its rebranding as…

Discover our fascinating content at issuu

explore